000			03428cam a2200409Ii 4500
988			_aSpringer_Medicine_2017
999			_c95672 _d95672 _x1
001			95672
003			ES-MaUEC
005			20230102112716.0
006			m o d
007			cr cnu|||unuuu
008			170329s2017 sz a ob 001 0 eng d
020			_a331950956X _q(electronic bk.)
020			_a9783319509563 _q(electronic bk.)
020			_z3319509551
020			_z9783319509556 _q(print)
040			_aN$T _cN$T _dGW5XE _dN$T _dYDX _dDKU _dCOO _dAZU _dUPM _dOCLCO _dUAB _dOCLCO _dESU _dVT2 _dJBG _dIAD _dICW _dICN _dILO _dOTZ _dOCLCQ _dIOG _dOCLCO _dU3W _dOCLCO _dOCLCA _dES-MaUEC _bspa
050		4	_aRC255 _b2017 EB
245	0	0	_aLiquid biopsies in solid tumors _cMassimo Cristofanilli, editors.
264		1	_aCham, Switzerland _bHumana Press _c2017.
300			_a1 recurso en línea _bilustraciones
336			_aTexto _btxt _2rdacontent
337			_aelectrónico _bc _2rdamedia
338			_arecurso electrónico _bcr _2rdacarrier
347			_atext file _bPDF _2rda
490	0		_aCancer drug discovery and development _x2196-9906
500			_aSpringerLink
504			_aIncluye referencias bibliográficas e índice
505	0		_a1. Blood-based diagnostics in solid tumors: an overview -- 2. Circulating tumor cells (CTCs) in primary disease: the seed for metastasis -- 3. Enumeration and molecular analysis of CTCs in metastatic disease: The breast cancer model -- 4. Epithelial-Mesenchymal Transition (EMT) and cancer stem cells (CSCs): The traveling metastasis -- 5. Detection and monitoring of circulating immune cells in solid tumors: shifting priorities -- 6. Circulating-free tumor DNA (ctDNA): the real-time liquid biopsy -- 7. CTCs and ctDNA: two tales of a complex biology -- 8. Exosome: decoding the messaging system.
520	3		_aThis volume, with chapters written by experts in the field of cancerous tumors, details the key factors associated with liquid biopsies in solid tumors: blood-based diagnostics; circulating tumor cells; enumeration and molecular analysis (association with breast cancer); epithelialmesenchymal transition; detection and monitoring; circulating-free tumor DNA; CTCs and ctDNA; and the exosome. The field of blood-based diagnostics is rapidly evolving demonstrating the possibility of real-time molecular analysis of cancer cells and their phenotype and genotype. Circulating Tumor Cell (CTCs) have demonstrated prognostic and predictive value in advanced cancer and represents a source of tumor cells for transcriptome and genomic analysis. Most recently, the detection of genomic abnormalities in the peripheral blood by sensitive and selective PCR methods (liquid biopsy) opened to the option of a comprehensive blood-based tumor analysis. Similar information can be obtained by analysis of exosome, a natural packaging and messaging system being explored in advanced malignancies. The final frontier is the evaluation of immune cells determinant of innate and adaptive immunity.
588	0		_aOnline resource; title from PDF title page (SpringerLink, viewed April 4, 2017).
650		7	_2embne _9139209 _aTumores
700	1		_aCristofanilli, Massimo _eeditor literario _990140
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=http://link.springer.com/10.1007/978-3-319-50956-3 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_b02/2018 _dz _e- _zSI